Stephanie Van De Wall, Ph.D.
Stephanie van de Wall, Ph.D.

Postdoctoral Research Scholar 
stephanie-vandewall@uiowa.edu  

Department of Pathology
25 S. Grand Ave, 1020 ML
University of Iowa
Iowa City, IA 52242

Lab: 319-335-9919
 

Training

2018: Ph.D., Department of Medical Microbiology, Tumor Virology and Cancer Immunotherapy, University of Groningen, Groningen, The Netherlands
2011: M.A., Infection and Immunity Program, Utrecht University, Utrecht, The Netherlands
2009: B.A., Biomedical Sciences, Specialization in Infectious Diseases, University of Edinburgh, Edinburgh, Scotland

Research

Immunity to influenza virus: Myeloid-T cell interactions in the lung

Publications Pubmed

  1. Anthony, SM, Van Braeckel-Budimir, N, Moioffer, SJ, van de Wall, S, Shan, Q, Vijay, R, Sompallae, R, Hartwig, SM, Jensen, IJ, Varga, SM, Butler, NS, Xue, HH, Badovinac, VP, Harty, JT.  Protective function and durability of mouse lymph node-resident memory CD8+ T cells. eLife 2021 Jun 18;10:e68662 DOI: 10.7554/eLife.68662
  2. Komdeur, FL, Singh, A, van de Wall, S, …, Daemen, T.  First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Mol Ther 2021 Feb 3;29(2):611-625.  DOI: 10.1016/j.ymthe.2020.11.002. Epub 2020 Nov 5. PMID: 33160073; PMCID: PMC7854293
  3. van de Wall, S, Badovinac, VP, Harty, JT.  Influenza-Specific Lung-Resident Memory CD8+ T Cells. Cold Spring Harb Perspect Biol 2021 Feb 1;13(2):a037978. DOI:10.1101/cshperspect.a037978 PMCID: PMC7849341
  4. van de Wall, S, Santegoets, KCM, van Houtum, E, Bull, C, Adema, GJ.  Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment. Trends Immunol. 2020 Apr;41(4):274-285. DOI: 10.1016/j.it.2020.02.001
  5. Singh, A, Koutsoumpli, G, van de Wall, S, Daemen, T.  An alphavirus-based therapeutic cancer vaccine: from design to clinical trial. Cancer Immunol Immunother, 2019 May;68(5):849-859.  DOI: 10.1007/s00262-018-2276-z
  6. van de Wall, S, Ljungberg, K, Ip, PP, Boerma, A, Knudsen, ML, Nijman, HW, Daemen, T.  Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. Oncoimmunology, 2018 Jul 26;7(10):e1487913. doi:10.1080/2162402x.2018.1487913 PMCID: PMC6169581
  7. Hartimath, SV, Draghiciu, O, van de Wall, S, Manuelli, V, Dierckx, RA, Nijman, HW, de Vries, EF.  Noninvasive monitoring of cancer therapy induced activated T cells using [(18)F]FB-IL-2 PET imaging. Oncoimmunology, 2016 Nov 18;6(1):e1248014. doi:10.1080/2162402x.2016.1248014 PMCID: PMC5283633
  8. Komdeur, FL, Prins, TM, van de Wall, S, Plat, A, Wisman, GBA, Hollema, H, Nijman, HW.  CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology, 2017 Jul 24;6(9):e1338230. doi:10.1080/2162402x.2017.1338230 PMCID: PMC559908
  9. van de Wall, S, Walczak, M, van Rooij, N, Hoogeboom, BN, Meijerhof, T, Nijman, HW, Daemen, T.  Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7. Vaccines (Basel), 2015 Mar 24;3(2):221-38. doi:10.3390/vaccines3020221 PMCID: PMC4494346
  10. van de Wall, S, Nijman, HW, Daemen, T.  HPV-specific immunotherapy: key role for immunomodulators. Anticancer Agents Med Chem, 2014 Feb;14(2):265-79. DOI : 10.2174/187152061402140128163306